219 related articles for article (PubMed ID: 10390011)
1. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
4. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
5. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
6. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning, expression pattern, and chromosomal localization of human CDKN2D/INK4d, an inhibitor of cyclin D-dependent kinases.
Okuda T; Hirai H; Valentine VA; Shurtleff SA; Kidd VJ; Lahti JM; Sherr CJ; Downing JR
Genomics; 1995 Oct; 29(3):623-30. PubMed ID: 8575754
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
9. Genes involved in melanoma: an overview of INK4a and other loci.
Castellano M; Parmiani G
Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
[TBL] [Abstract][Full Text] [Related]
10. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
11. Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.
Fink JR; LeBien TW
Exp Hematol; 2001 Apr; 29(4):490-8. PubMed ID: 11301189
[TBL] [Abstract][Full Text] [Related]
12. Backbone dynamics of the CDK inhibitor p19(INK4d) studied by 15N NMR relaxation experiments at two field strengths.
Renner C; Baumgartner R; Noegel AA; Holak TA
J Mol Biol; 1998; 283(1):221-9. PubMed ID: 9761685
[TBL] [Abstract][Full Text] [Related]
13. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
14. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
15. Lack of germline CDK6 mutations in familial melanoma.
Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
[TBL] [Abstract][Full Text] [Related]
16. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
17. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Arcellana-Panlilio MY; Egeler RM; Ujack E; Magliocco A; Stuart GC; Robbins SM; Coppes MJ
Genes Chromosomes Cancer; 2002 Oct; 35(2):176-81. PubMed ID: 12203782
[TBL] [Abstract][Full Text] [Related]
18. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
Zuo L; Weger J; Yang Q; Goldstein AM; Tucker MA; Walker GJ; Hayward N; Dracopoli NC
Nat Genet; 1996 Jan; 12(1):97-9. PubMed ID: 8528263
[No Abstract] [Full Text] [Related]
20. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
Molven A; Grimstvedt MB; Steine SJ; Harland M; Avril MF; Hayward NK; Akslen LA
Genes Chromosomes Cancer; 2005 Sep; 44(1):10-8. PubMed ID: 15880589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
